Microbix Biosystems Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Microbix Biosystems'in gelirinin yıllık 22.7% oranında artacağı tahmin edilmektedir. EPS'nin büyümesi yıllık 23.1% oranında artması beklenmektedir.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

23.1%

EPS büyüme oranı

Biotechs kazanç büyümesi	36.7%
Gelir büyüme oranı	22.7%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	15 Aug 2024

Gelecekteki son büyüme güncellemeleri

Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price

Feb 17

Recent updates

Microbix Biosystems' (TSE:MBX) Shareholders Should Assess Earnings With Caution

Aug 22

Why Microbix Biosystems' (TSE:MBX) Earnings Are Weaker Than They Seem

Feb 21

Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price

Feb 17

Microbix Biosystems Inc.'s (TSE:MBX) Shares Climb 29% But Its Business Is Yet to Catch Up

Dec 23

Is Microbix Biosystems (TSE:MBX) Using Debt Sensibly?

Nov 03

Is Microbix Biosystems (TSE:MBX) Using Debt In A Risky Way?

Jul 22

Some Shareholders Feeling Restless Over Microbix Biosystems Inc.'s (TSE:MBX) P/S Ratio

May 17

Time To Worry? Analysts Are Downgrading Their Microbix Biosystems Inc. (TSE:MBX) Outlook

Dec 27

One Microbix Biosystems Inc. (TSE:MBX) Analyst Just Made A Major Cut To Next Year's Estimates

Dec 28

Is Microbix Biosystems (TSE:MBX) A Risky Investment?

Oct 14

Microbix Biosystems Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 15

A Look At The Fair Value Of Microbix Biosystems Inc. (TSE:MBX)

May 17

Most Shareholders Will Probably Find That The CEO Compensation For Microbix Biosystems Inc. (TSE:MBX) Is Reasonable

Mar 24

We Think Microbix Biosystems (TSE:MBX) Has A Fair Chunk Of Debt

Jan 29

Kazanç ve Gelir Büyüme Tahminleri

TSX:MBX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CAD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2026	39	N/A	N/A	N/A	1
9/30/2025	29	N/A	N/A	N/A	1
9/30/2024	25	N/A	N/A	N/A	1
6/30/2024	23	5	0	2	N/A
3/31/2024	24	4	2	3	N/A
12/31/2023	22	4	0	1	N/A
9/30/2023	17	0	-2	-1	N/A
6/30/2023	17	-3	-2	1	N/A
3/31/2023	16	-1	-1	1	N/A
12/31/2022	17	0	1	3	N/A
9/30/2022	19	2	1	3	N/A
6/30/2022	20	3	4	5	N/A
3/31/2022	21	4	1	2	N/A
12/31/2021	20	4	1	2	N/A
9/30/2021	19	3	1	2	N/A
6/30/2021	16	-3	-1	0	N/A
3/31/2021	13	-4	0	2	N/A
12/31/2020	12	-6	-1	0	N/A
9/30/2020	11	-6	-1	0	N/A
6/30/2020	11	-1	0	1	N/A
3/31/2020	12	-1	-1	0	N/A
12/31/2019	13	0	0	0	N/A
9/30/2019	13	0	0	0	N/A
6/30/2019	13	-8	0	0	N/A
3/31/2019	13	-8	0	0	N/A
12/31/2018	12	-9	0	1	N/A
9/30/2018	13	-9	-2	-1	N/A
6/30/2018	12	-1	-2	-1	N/A
3/31/2018	11	-1	N/A	-1	N/A
12/31/2017	11	-1	N/A	-1	N/A
9/30/2017	10	-4	N/A	0	N/A
6/30/2017	11	-2	N/A	1	N/A
3/31/2017	10	-2	N/A	1	N/A
12/31/2016	10	-2	N/A	1	N/A
9/30/2016	10	1	N/A	1	N/A
6/30/2016	8	0	N/A	1	N/A
3/31/2016	8	0	N/A	0	N/A
12/31/2015	8	0	N/A	0	N/A
9/30/2015	9	1	N/A	1	N/A
6/30/2015	9	0	N/A	0	N/A
3/31/2015	9	0	N/A	0	N/A
12/31/2014	8	0	N/A	-1	N/A
9/30/2014	8	0	N/A	-1	N/A
6/30/2014	9	1	N/A	1	N/A
3/31/2014	8	1	N/A	1	N/A
12/31/2013	9	1	N/A	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MBX 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.3% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: MBX 'un kazançlarının Canadian pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: MBX şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: MBX şirketinin gelirinin (yıllık 22.7% ) Canadian pazarından (yıllık 6.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MBX şirketinin gelirinin (yıllık 22.7% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MBX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Microbix Biosystems Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price

Microbix Biosystems Inc. Provides Earnings Guidance for the Full-Year Fiscal 2024

Price target decreased to CA$1.13

Consensus forecasts updated

Consensus EPS estimates fall by 28%

Microbix Biosystems Inc. Provides Earnings Guidance for the Fiscal Year 2022

Recent updates

President recently sold CA$73k worth of stock

Microbix Biosystems Inc. to Present Results of Novel Quality Assessment Product At the European Meeting on Molecular Diagnostics

Microbix Biosystems' (TSE:MBX) Shareholders Should Assess Earnings With Caution

Third quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.006 loss in 3Q 2023)

Microbix Biosystems Inc. to Report Q3, 2024 Results on Aug 13, 2024

Microbix Biosystems Inc. Presents HCV FLOQSwab Format Test Control at ADLM

Second quarter 2024 earnings released: EPS: CA$0.003 (vs CA$0 in 2Q 2023)

Microbix Biosystems Inc. to Report Q2, 2024 Results on May 15, 2024

Microbix Biosystems Inc. Unveils Test Controls for Head and Neck Cancer

New minor risk - Insider selling

Microbix Biosystems Inc., Annual General Meeting, Mar 27, 2024

Why Microbix Biosystems' (TSE:MBX) Earnings Are Weaker Than They Seem

Microbix Biosystems Inc. (TSE:MBX) Just Reported Earnings, And Analysts Cut Their Target Price

First quarter 2024 earnings released: EPS: CA$0.018 (vs CA$0.009 loss in 1Q 2023)

Microbix Biosystems Inc. to Report Q1, 2024 Results on Feb 14, 2024

Microbix Biosystems Inc., Annual General Meeting, Mar 27, 2024

Microbix Biosystems Inc.'s (TSE:MBX) Shares Climb 29% But Its Business Is Yet to Catch Up

Full year 2023 earnings: Revenues miss analyst expectations

Microbix Biosystems Inc. Provides Earnings Guidance for the Full-Year Fiscal 2024

Is Microbix Biosystems (TSE:MBX) Using Debt Sensibly?

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.005 profit in 3Q 2022)

Microbix Successfully Upgrades Logistics Software Systems Achieves “Go-Live” with New ERP and eQMS Solutions

Microbix Biosystems Inc. Presents Results of STI Test Controls at AACC

Is Microbix Biosystems (TSE:MBX) Using Debt In A Risky Way?

Microbix Biosystems Inc. Presents Results of STI Test Controls at ASM Microbe Microbe FLOQ

Some Shareholders Feeling Restless Over Microbix Biosystems Inc.'s (TSE:MBX) P/S Ratio

Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0.005 in 2Q 2022)

First quarter 2023 earnings: Revenues miss analyst expectations

Microbix Biosystems Inc. Launches QAP to Support "Monkeypox" Testing

Microbix Biosystems Inc., Annual General Meeting, Mar 29, 2023

Time To Worry? Analysts Are Downgrading Their Microbix Biosystems Inc. (TSE:MBX) Outlook

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CA$1.13

Insufficient new directors

Microbix Biosystems Inc. Presenting Test-Workflow Validation Results At EMMD

President recently sold CA$70k worth of stock

President exercised options to buy CA$191k worth of stock.

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Microbix Biosystems (TSE:MBX) Has A Pretty Healthy Balance Sheet

President exercised options to buy CA$182k worth of stock.

Microbix Biosystems Inc. Presenting Test Validation Methods at AACC

Microbix Biosystems' (TSE:MBX) Solid Profits Have Weak Fundamentals

Consensus EPS estimates fall by 28%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Microbix Biosystems Inc. Provides Earnings Guidance for the Fiscal Year 2022

Microbix Biosystems Inc. to Present Performance Results of its Quality Assessment Product at the 2022 Clinical Virology Symposium of the American Society for Microbiology

Price target decreased to CA$1.50

Insufficient new directors

President exercised options to buy CA$206k worth of stock.

Microbix Biosystems Inc. Presents HPV Product Results at EUROGIN

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CA$1.50

Microbix Biosystems (TSE:MBX) Seems To Use Debt Quite Sensibly

Microbix Biosystems Inc. Launches Omicron Variant Test Control

President exercised options to buy CA$274k worth of stock.

One Microbix Biosystems Inc. (TSE:MBX) Analyst Just Made A Major Cut To Next Year's Estimates

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Microbix Biosystems Inc. Launches Multiplex Respiratory PCR-Test Control

Insufficient new directors

Chief Financial Officer recently sold CA$68k worth of stock

Independent Chairman of the Board exercised options to buy CA$426k worth of stock.

Independent Director exercised options to buy CA$115k worth of stock.

Independent Director exercised options to buy CA$117k worth of stock.

Is Microbix Biosystems (TSE:MBX) A Risky Investment?

President exercised options to buy CA$107k worth of stock.

Microbix Biosystems Inc. Presenting Product Results At AACC

Microbix Biosystems Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions